New article in Diabetes Care
/Vascular protective effects of methylglyoxal modified-autoantibodies in type 1 diabetes?
In the paper: Autoantibodies against methylglyoxal-modified apolipoprotein B100 and ApoB100 peptide are associated with less coronary artery atherosclerosis and retinopathy in long-term type 1 diabetes Kari Anne Sveen and co-workers investigated the association of immune responses of methylglyoxal (MGO), a reactive aldehyde forming advanced glycation end products (AGEs), resulting in anti-AGE-specific autoantibodies, with coronary atherosclerosis and proliferative retinopathy in type 1 diabetes of long duration.
We found that autoantibodies against AGE-modified apoB100 were inversely associated with coronary atherosclerosis and PDR, suggesting vascular protective effects of these autoantibodies. These findings are interesting for potential biological treatments of these complications in type 1 diabetes.
Kari Anne Sveen
Photo: Unsplash